IntroductionMelanoma is one of the most invasive and deadly types of skin cancers. Various methods such as radiotherapy, chemotherapy, immunotherapy, and surgery are used to treat this type of cancer. HSP90 has a fundamental role in cancer oncogenesis, so this study aimed to determine the effect of HSP90 inhibitor on HMGA1, HMGB2, and NF-KB signaling pathways in melanoma cell lines (A-375 and SK-MEL-28). Materials & methodsMelanoma cancer cell lines were treated with HSP90 inhibitor for 72 h. The expression of HSP90 was determined by western blotting assay. HMGA1, HMGB2, and NF-KB expression were assessed by qPCR and Western blotting. The cell viability of cancer cells was assessed by MTT assay. Besides, a rescue experiment was conducted to determine the effect of simultaneous transfection of NF-kB siRNA and HSP90 inhibitor. ResultsHSP90 inhibitor reduced HSP90 protein expression in a time-dependent manner in both cell lines. HSP90 inhibitor attenuated HMGA1, HMGB2, and NF-KB expression in A-375 and SK-MEL-28 cell lines. MTT evaluation showed reduced cell viability after HSP90 inhibitor addition. Furthermore, the results of rescue experiments showed that the HSP90 inhibitor plays a reducing role of HMGB1 and HMGB2 via the NF-KB signaling pathway. ConclusionThe results of the present study determine a potential role of anti-HSP90 in melanoma cancer cell oncogenesis via modulating HMGB2, HMGA1 through the NF-KB signaling pathway.